Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Max dimerization protein 4 (MXD4) is a transcriptional repressor that forms heterodimers with the MAX protein, enabling it to bind DNA at E-box sequences and repress transcription of target genes. MXD4 competes with MYC for binding to MAX; whereas MYC/MAX heterodimers activate transcription and drive cell proliferation, MXD4/MAX heterodimers repress MYC target genes, antagonizing MYC function and promoting cell differentiation or quiescence. Studies indicate that MXD4 acts as a tumor suppressor and is involved in regulating the balance between cell proliferation and differentiation. Aberrant expression or genetic alteration of MXD4 has been associated with human cancers, such as NUTM1-rearranged sarcomas and acute myeloid leukemia, where it modulates the MYC transcriptional network and impacts self-renewal and tumorigenesis. MXD4 belongs to the basic helix-loop-helix-leucine zipper (bHLH-LZ) family of transcription factors and is classified as a Max dimerization (MAD/MXD) protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Max dimerization protein 4 (MXD4).